| 1 |
Hristov AC, Tejasvi T, Wilcox RA. Cutaneous T-cell lymphomas: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol 2023;98:193-209. [PMID: 36226409 DOI: 10.1002/ajh.26760] [Reference Citation Analysis]
|
| 2 |
Hughes MS, Sterling CH, Varadhan R, Ambinder RF, Jones RJ, Sweren RJ, Rozati S, Bolaños-Meade J, Luznik L, Imus PH, Ali SA, Borrello IM, Huff CA, Jain T, Ambinder A, DeZern AE, Gocke CB, Gladstone DE, Swinnen LJ, Wagner-Johnston ND, Fuchs EJ. Mismatched donor transplantation with post-transplantation cyclophosphamide for advanced cutaneous T-cell lymphoma: a single-center retrospective study. Leuk Lymphoma 2022;63:2987-91. [PMID: 35915978 DOI: 10.1080/10428194.2022.2105330] [Reference Citation Analysis]
|
| 3 |
Elliott J, Ahlawat S, Prince HM, Kennedy G, Wells J, Huang G, Collins J, Bardy P, Van Der Weyden C, Ritchie D, Khot A. Long-term outcomes for allogeneic bone marrow transplantation in Sezary syndrome and mycosis fungoides. Bone Marrow Transplant 2022. [PMID: 36028756 DOI: 10.1038/s41409-022-01787-3] [Reference Citation Analysis]
|
| 4 |
Keenan M. Pharmacotherapeutics of aprepitant and pregabalin in neuropathic pain and refractory pruritus in a patient diagnosed with a cutaneous T-cell lymphoma. Journal of Prescribing Practice 2022;4:362-367. [DOI: 10.12968/jprp.2022.4.8.362] [Reference Citation Analysis]
|
| 5 |
Kim YH. What factors guide treatment selection in mycosis fungoides and Sezary syndrome? Hematology Am Soc Hematol Educ Program 2021;2021:303-12. [PMID: 34889422 DOI: 10.1182/hematology.2021000263] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 6 |
Hristov AC, Tejasvi T, A Wilcox R. Cutaneous T-cell lymphomas: 2021 update on diagnosis, risk-stratification, and management. Am J Hematol 2021;96:1313-28. [PMID: 34297414 DOI: 10.1002/ajh.26299] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 7 |
Brumfiel CM, Patel MH, Puri P, Besch-Stokes J, Lester S, Rule WG, Khera N, Sluzevich JC, DiCaudo DJ, Comfere N, Bennani NN, Rosenthal AC, Pittelkow MR, Mangold AR. How to Sequence Therapies in Mycosis Fungoides. Curr Treat Options Oncol 2021;22:101. [PMID: 34570278 DOI: 10.1007/s11864-021-00899-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 8 |
Xu S, Foss F. New nonchemotherapy treatment options for cutaneous T-cell lymphomas. Expert Rev Anticancer Ther 2021;21:1017-28. [PMID: 33554707 DOI: 10.1080/14737140.2021.1882859] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 9 |
Weng WK, Arai S, Rezvani A, Johnston L, Lowsky R, Miklos D, Shizuru J, Muffly L, Meyer E, Negrin RS, Wang E, Almazan T, Million L, Khodadoust M, Li S, Hoppe RT, Kim YH. Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma. Blood Adv 2020;4:4474-82. [PMID: 32941647 DOI: 10.1182/bloodadvances.2020001627] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 10 |
Dodero A, Corradini P. Allogeneic Stem‐cell Transplantation. The Peripheral T‐Cell Lymphomas 2021. [DOI: 10.1002/9781119671336.ch23] [Reference Citation Analysis]
|
| 11 |
de Masson A, Peffault de Latour R, Ram-wolff C, Bagot M. Traitement des lymphomes T cutanés par allogreffe de cellules souches hématopoïétiques. Annales de Dermatologie et de Vénéréologie - FMC 2021;1:187-192. [DOI: 10.1016/j.fander.2020.07.004] [Reference Citation Analysis]
|
| 12 |
Prince HM, Abeyakoon C. Allogeneic haematopoietic stem cell transplantation for advanced stage mycosis fungoides and Sézary syndrome: never-late, never-never? Bone Marrow Transplant 2021;56:1232-4. [PMID: 33526916 DOI: 10.1038/s41409-020-01150-4] [Reference Citation Analysis]
|
| 13 |
Domingo-Domenech E, Duarte RF, Boumedil A, Onida F, Gabriel I, Finel H, Arcese W, Browne P, Beelen D, Kobbe G, Veelken H, Arranz R, Greinix H, Lenhoff S, Poiré X, Ribera JM, Thompson J, Zuckerman T, Mufti GJ, Cortelezzi A, Olavarria E, Dreger P, Sureda A, Montoto S. Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides and Sézary syndrome. An updated experience of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant 2021;56:1391-401. [PMID: 33420392 DOI: 10.1038/s41409-020-01197-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 14 |
Kamijo H, Miyagaki T. Mycosis Fungoides and Sézary Syndrome: Updates and Review of Current Therapy. Curr Treat Options Oncol 2021;22:10. [PMID: 33415447 DOI: 10.1007/s11864-020-00809-w] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 15 |
Bhabha FK, McCormack C, Wells J, Campbell BA, Newland K, Lade S, Buelens O, Joske D, Shortt J, Mapp S, Radeski D, Hertzberg M, Khot A, Van Der Weyden C, Khoo C, Hawkes E, Prince HM. Mycosis fungoides and Sézary syndrome: Australian clinical practice statement. Australas J Dermatol 2021;62:e8-e18. [PMID: 33368169 DOI: 10.1111/ajd.13467] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 16 |
Ohtsuka M, Hamada T, Miyagaki T, Shimauchi T, Yonekura K, Kiyohara E, Fujita H, Izutsu K, Okuma K, Kawai K, Koga H, Sugaya M. Outlines of the Japanese guidelines for the management of primary cutaneous lymphomas 2020. J Dermatol 2021;48:e49-71. [PMID: 33245165 DOI: 10.1111/1346-8138.15707] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 17 |
Dumont M, Peffault de Latour R, Ram-Wolff C, Bagot M, de Masson A. Allogeneic Hematopoietic Stem Cell Transplantation in Cutaneous T-Cell Lymphomas. Cancers (Basel) 2020;12:E2856. [PMID: 33023002 DOI: 10.3390/cancers12102856] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 18 |
Stolearenco V, Namini MRJ, Hasselager SS, Gluud M, Buus TB, Willerslev-Olsen A, Ødum N, Krejsgaard T. Cellular Interactions and Inflammation in the Pathogenesis of Cutaneous T-Cell Lymphoma. Front Cell Dev Biol 2020;8:851. [PMID: 33015047 DOI: 10.3389/fcell.2020.00851] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 19 |
Kanda-Kato M, Yoshioka S, Ishikawa T. Haploidentical Hematopoietic Cell Transplantation Using Posttransplant Cyclophosphamide for Sézary Syndrome. Case Rep Oncol 2020;13:1053-8. [PMID: 33082748 DOI: 10.1159/000509347] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 20 |
Sézary syndrome. Skin Lymphoma 2020. [DOI: 10.1002/9781119485933.ch4] [Reference Citation Analysis]
|
| 21 |
Dimitriou F, Schanz U, Nair G, Kimeswenger S, Brüggen MC, Hoetzenecker W, French LE, Dummer R, Cozzio A, Guenova E. Long-Term Disease Control After Allogeneic Hematopoietic Stem Cell Transplantation in Primary Cutaneous T-Cell Lymphoma; Results From a Single Institution Analysis. Front Med (Lausanne) 2020;7:290. [PMID: 32714935 DOI: 10.3389/fmed.2020.00290] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 22 |
. Mycosis fungoides. Skin Lymphoma. Wiley; 2020. pp. 23-112. [DOI: 10.1002/9781119485933.ch3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 23 |
Isufi I, Seropian S, Gowda L, Wilson LD, Roberts K, Girardi M, Perreault S, Foss F. Outcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma Delta T cell lymphomas. Leukemia & Lymphoma 2020;61:2955-61. [DOI: 10.1080/10428194.2020.1790555] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 24 |
Lewis DJ, Rook AH. Mogamulizumab in the treatment of advanced mycosis fungoides and Sézary syndrome: safety and efficacy. Expert Rev Anticancer Ther 2020;20:447-52. [PMID: 32320304 DOI: 10.1080/14737140.2020.1760096] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 25 |
Mori T, Shiratori S, Suzumiya J, Kurokawa M, Shindo M, Naoyuki U, Katsuto T, Miyamoto T, Morishige S, Hirokawa M, Fukuda T, Atsuta Y, Suzuki R. Outcome of allogeneic hematopoietic stem cell transplantation for mycosis fungoides and Sézary syndrome. Hematol Oncol 2020;38:266-71. [PMID: 32011008 DOI: 10.1002/hon.2719] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 26 |
Dalal M, Mitchell S, Mccloskey C, Zagadailov E, Gautam A. The clinical and humanistic burden of cutaneous T-cell lymphomas and response to conventional and novel therapies: results of a systematic review. Expert Review of Hematology 2020;13:405-19. [DOI: 10.1080/17474086.2020.1717945] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 27 |
Iqbal M, Reljic T, Ayala E, Sher T, Murthy H, Roy V, Foran J, Tun H, Kumar A, Kharfan-dabaja MA. Efficacy of Allogeneic Hematopoietic Cell Transplantation in Cutaneous T Cell Lymphoma: Results of a Systematic Review and Meta-Analysis. Biology of Blood and Marrow Transplantation 2020;26:76-82. [DOI: 10.1016/j.bbmt.2019.08.019] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 28 |
Querfeld C, Rosen ST, Duvic M. Cutaneous T-Cell Lymphoma and Cutaneous B-Cell Lymphoma. Abeloff's Clinical Oncology 2020. [DOI: 10.1016/b978-0-323-47674-4.00104-3] [Reference Citation Analysis]
|
| 29 |
Mahmut Y. Achievement of cure following allogeneic HSCT with Flu-Bu regimen in a patient with severe mycosis fungoides and Sezary Syndrome. Arch Case Rep 2019;3:054-055. [DOI: 10.29328/journal.acr.1001025] [Reference Citation Analysis]
|
| 30 |
Babakoohi S. Cutaneous T Cell Lymphoma: Ready to Enter the World of Allogeneic Transplant? Biol Blood Marrow Transplant 2020;26:e5-6. [PMID: 31733298 DOI: 10.1016/j.bbmt.2019.11.009] [Reference Citation Analysis]
|
| 31 |
Martinez XU, Di Raimondo C, Abdulla FR, Zain J, Rosen ST, Querfeld C. Leukaemic variants of cutaneous T-cell lymphoma: Erythrodermic mycosis fungoides and Sézary syndrome. Best Pract Res Clin Haematol 2019;32:239-52. [PMID: 31585624 DOI: 10.1016/j.beha.2019.06.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 32 |
Dai J, Almazan TH, Hong EK, Khodadoust MS, Arai S, Weng WK, Kim YH. Potential Association of Anti-CCR4 Antibody Mogamulizumab and Graft-vs-Host Disease in Patients With Mycosis Fungoides and Sézary Syndrome. JAMA Dermatol 2018;154:728-30. [PMID: 29800117 DOI: 10.1001/jamadermatol.2018.0884] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 33 |
Hristov AC, Tejasvi T, Wilcox RA. Mycosis fungoides and Sézary syndrome: 2019 update on diagnosis, risk-stratification, and management. Am J Hematol 2019;94:1027-41. [PMID: 31313347 DOI: 10.1002/ajh.25577] [Cited by in Crossref: 49] [Cited by in F6Publishing: 52] [Article Influence: 12.3] [Reference Citation Analysis]
|
| 34 |
Specht L, Skov L. Cutaneous Lymphomas. Clin Oncol (R Coll Radiol) 2019;31:797-807. [PMID: 31405542 DOI: 10.1016/j.clon.2019.07.018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 35 |
Sivanand A, Surmanowicz P, Alhusayen R, Hull P, Litvinov IV, Zhou Y, Gniadecki R. Immunotherapy for Cutaneous T-Cell Lymphoma: Current Landscape and Future Developments. J Cutan Med Surg 2019;23:537-44. [PMID: 31353944 DOI: 10.1177/1203475419867610] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 36 |
Novelli S, Monter A, Pilar García-Muret M, Martino R, Briones J, Sierra J. Discussion on the indication of allogeneic stem cell transplantation for advanced cutaneous T cell lymphomas. Int J Hematol 2019;110:406-10. [PMID: 31317515 DOI: 10.1007/s12185-019-02707-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 37 |
Shanbhag S, Wagner-Johnston N, Ambinder RF, Jones RJ. Is It Time to Revisit the Role of Allogeneic Transplantation in Lymphoma? Curr Oncol Rep 2019;21:65. [PMID: 31183579 DOI: 10.1007/s11912-019-0809-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 38 |
Hunter BD, Chen YB, Jacobson CA. Allogeneic Stem Cell Transplantation and Chimeric Antigen Receptor (CAR) T-Cell Therapy for the Treatment of Non-Hodgkin Lymphoma. Hematol Oncol Clin North Am 2019;33:687-705. [PMID: 31229163 DOI: 10.1016/j.hoc.2019.03.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 39 |
Leuchte K, Schlaak M, Stadler R, Theurich S, von Bergwelt-baildon M. Innovative Behandlungskonzepte mit Modulation der Mikroumgebung beim kutanen T-Zell-Lymphom. Kompass Dermatol 2019;7:111-119. [DOI: 10.1159/000500890] [Reference Citation Analysis]
|
| 40 |
Arslan S, Hosing C. Hematopoietic Stem Cell Transplantation for Rare Hematological Malignancies. Hematopoietic Cell Transplantation for Malignant Conditions 2019. [DOI: 10.1016/b978-0-323-56802-9.00019-5] [Reference Citation Analysis]
|
| 41 |
Zain J. Transplantation. Cancer Treatment and Research 2019. [DOI: 10.1007/978-3-319-99716-2_13] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 42 |
Van Der Weyden C, Dickinson M, Whisstock J, Prince HM. Brentuximab vedotin in T-cell lymphoma. Expert Review of Hematology 2018;12:5-19. [DOI: 10.1080/17474086.2019.1558399] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 43 |
Gilson D, Whittaker S, Child F, Scarisbrick J, Illidge T, Parry E, Mohd Mustapa M, Exton L, Kanfer E, Rezvani K, Dearden C, Morris S, Mchenry P, Leslie T, Wakelin S, Hunasehally R, Cork M, Johnston G, Chiang N, Worsnop F, Salim A, Buckley D, Petrof G, Callachand N, Flavell T, Salad A. British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018. Br J Dermatol 2019;180:496-526. [DOI: 10.1111/bjd.17240] [Cited by in Crossref: 68] [Cited by in F6Publishing: 71] [Article Influence: 13.6] [Reference Citation Analysis]
|
| 44 |
Demina OM, Akilov OE, Rumyantsev AG. Cutaneous T-cell lymphomas: modern data of pathogenesis, clinics and therapy. Onkogematologiâ 2018;13:25-38. [DOI: 10.17650/1818-8346-2018-13-3-25-38] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 45 |
Hosoi H, Hatanaka K, Murata S, Mushino T, Kuriyama K, Nishikawa A, Hanaoka N, Tamura S, Nakakuma H, Sonoki T. Long-term complete remission of early hematological relapse after discontinuation of immunosuppressants following allogeneic transplantation for Sezary syndrome. Hematol Rep 2018;10:7497. [PMID: 30283619 DOI: 10.4081/hr.2018.7497] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 46 |
Friedrichs B, Stelljes M, Schmitz N. The role of allogeneic stem cell transplantation in T-cell lymphoma. Current Opinion in Oncology 2018;30:301-7. [DOI: 10.1097/cco.0000000000000473] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 47 |
Schmitz N, Lenz G, Stelljes M. Allogeneic hematopoietic stem cell transplantation for T-cell lymphomas. Blood 2018;132:245-53. [PMID: 29699989 DOI: 10.1182/blood-2018-01-791335] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 7.4] [Reference Citation Analysis]
|
| 48 |
Ettler J, Arenberger P, Polívka J. Current therapeutical options in primary cutaneous T-cell lymphomas. Dermatol praxi 2018;12:31-35. [DOI: 10.36290/der.2018.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 49 |
Cudillo L, Cerretti R, Picardi A, Mariotti B, De Angelis G, Cantonetti M, Postorino M, Ceresoli E, De Santis G, Nasso D, Pisani F, Scala E, Di Piazza F, Lanti A; William Arcese for the Rome Transplant Network. Allogeneic hematopoietic stem cell transplantation in Primary Cutaneous T Cell Lymphoma. Ann Hematol 2018;97:1041-8. [PMID: 29442161 DOI: 10.1007/s00277-018-3275-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 50 |
Nicolay JP, Goerdt S. Kutane Lymphome beim alten und geriatrischen Patienten. Geriatrische Onkologie 2018. [DOI: 10.1007/978-3-662-48727-3_43] [Reference Citation Analysis]
|
| 51 |
Chung CG, Poligone B, Heald PW. Cutaneous T-Cell Lymphoma. Biologic and Systemic Agents in Dermatology 2018. [DOI: 10.1007/978-3-319-66884-0_33] [Reference Citation Analysis]
|
| 52 |
Gauthier J, Chantepie S, Bouabdallah K, Jost E, Nguyen S, Gac A, Damaj G, Duléry R, Michallet M, Delage J, Lewalle P, Morschhauser F, Salles G, Yakoub-agha I, Cornillon J. Allogreffe de cellules souches hématopoïétiques dans la lymphome de Hodgkin, le lymphome du manteau et autres hémopathies lymphoïdes rares : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC). Bulletin du Cancer 2017;104:S112-20. [DOI: 10.1016/j.bulcan.2017.06.020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 53 |
van Santen S, Vermeer MH, Willemze R. Classification and recommended treatment options for folliculotropic mycosis fungoides. Expert Opinion on Orphan Drugs 2017;6:35-45. [DOI: 10.1080/21678707.2018.1406796] [Reference Citation Analysis]
|
| 54 |
Berg S, Villasenor-Park J, Haun P, Kim EJ. Multidisciplinary Management of Mycosis Fungoides/Sézary Syndrome. Curr Hematol Malig Rep 2017;12:234-43. [PMID: 28540671 DOI: 10.1007/s11899-017-0387-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 55 |
Burgstaller S, Thaler J. Disease control with brentuximab vedotin in an aged patient with primary cutaneous anaplastic large-cell lymphoma. memo 2017;10:170-172. [DOI: 10.1007/s12254-017-0325-5] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 56 |
Kharfan-Dabaja MA, Kumar A, Ayala E, Hamadani M, Reimer P, Gisselbrecht C, d'Amore F, Jantunen E, Ishida T, Bazarbachi A, Foss F, Advani R, Fenske TS, Lazarus HM, Friedberg JW, Aljurf M, Sokol L, Tobinai K, Tse E, Burns LJ, Chavez JC, Reddy NM, Suzuki R, Ahmed S, Nademanee A, Mohty M, Gopal AK, Fanale MA, Pro B, Moskowitz AJ, Sureda A, Perales MA, Carpenter PA, Savani BN. Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2017;23:1826-1838. [PMID: 28797780 DOI: 10.1016/j.bbmt.2017.07.027] [Cited by in Crossref: 96] [Cited by in F6Publishing: 101] [Article Influence: 16.0] [Reference Citation Analysis]
|
| 57 |
Heitmiller K, Barnes J, Chen ST. Cutaneous Lymphoma—Inpatient Considerations. Curr Derm Rep 2017;6:63-76. [DOI: 10.1007/s13671-017-0173-x] [Reference Citation Analysis]
|
| 58 |
Lewis DJ, Duvic M. Forodesine in the treatment of cutaneous T-cell lymphoma. Expert Opin Investig Drugs 2017;26:771-5. [PMID: 28447489 DOI: 10.1080/13543784.2017.1324569] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 59 |
Nicolay JP, Goerdt S. Kutane Lymphome beim alten und geriatrischen Patienten. Geriatrische Onkologie 2017. [DOI: 10.1007/978-3-662-49083-9_43-1] [Reference Citation Analysis]
|
| 60 |
Eich HT, Elsayad K. Radiation Therapy in Peripheral T-Cell and Cutaneous Lymphomas. Radiation Oncology 2017. [DOI: 10.1007/978-3-319-52619-5_30-1] [Reference Citation Analysis]
|
| 61 |
Menter T, Medani H, Olavarria E, Kanfer E, Naresh KN. Pathology findings in patients with cutaneous T-cell lymphomas treated with allogeneic haematopoietic stem cell transplantation. Br J Haematol 2018;180:904-8. [DOI: 10.1111/bjh.14479] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 62 |
Ma H, Abdul-Hay M. T-cell lymphomas, a challenging disease: types, treatments, and future. Int J Clin Oncol 2017;22:18-51. [PMID: 27743148 DOI: 10.1007/s10147-016-1045-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 63 |
Scarisbrick JJ. New drugs in cutaneous T-cell lymphomas. Current Opinion in Oncology 2016;28:384-9. [DOI: 10.1097/cco.0000000000000311] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 64 |
Bagherani N, Smoller BR. An overview of cutaneous T cell lymphomas. F1000Res 2016;5:F1000 Faculty Rev-1882. [PMID: 27540476 DOI: 10.12688/f1000research.8829.1] [Cited by in Crossref: 46] [Cited by in F6Publishing: 50] [Article Influence: 6.6] [Reference Citation Analysis]
|
| 65 |
Rozati S, Kim YH. Experimental treatment strategies in primary cutaneous T-cell lymphomas. Curr Opin Oncol 2016;28:166-71. [PMID: 26844985 DOI: 10.1097/CCO.0000000000000272] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
|
